[{"id":"464e9e3c-dbca-4658-a0d8-81ceb79ad5f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05555212","created_at":"2022-09-26T14:56:19.950Z","updated_at":"2024-07-02T16:35:52.081Z","phase":"Phase 1","brief_title":"To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation","source_id_and_acronym":"NCT05555212","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QLH11811"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-28"}]